Janet Liang Sells 12,475 Shares of Oscar Health (NYSE:OSCR) Stock

Oscar Health, Inc. (NYSE:OSCR) insider Janet Liang sold 12,475 shares of the company’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $21.94, for a total transaction of $273,701.50. Following the sale, the insider directly owned 259,057 shares of the company’s stock, valued at approximately $5,683,710.58. This trade represents a 4.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Oscar Health Stock Up 4.2%

Shares of Oscar Health stock opened at $24.59 on Friday. The company has a fifty day moving average price of $18.39 and a 200 day moving average price of $16.06. The company has a current ratio of 1.11, a quick ratio of 1.11 and a debt-to-equity ratio of 0.26. Oscar Health, Inc. has a twelve month low of $10.69 and a twelve month high of $25.58. The stock has a market cap of $7.41 billion, a price-to-earnings ratio of -41.68, a price-to-earnings-growth ratio of 1.65 and a beta of 2.37.

Oscar Health (NYSE:OSCR) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $2.07 earnings per share for the quarter, topping analysts’ consensus estimates of $1.11 by $0.96. The firm had revenue of $4.65 billion during the quarter, compared to analysts’ expectations of $4.90 billion. Oscar Health had a negative net margin of 0.30% and a negative return on equity of 3.26%. The firm’s revenue was up 52.6% on a year-over-year basis. During the same period in the prior year, the company earned $0.92 EPS. Equities research analysts forecast that Oscar Health, Inc. will post 0.47 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on OSCR shares. Robert W. Baird lifted their target price on Oscar Health from $15.00 to $19.00 and gave the stock a “neutral” rating in a research report on Thursday, May 7th. Wolfe Research assumed coverage on Oscar Health in a research note on Tuesday, May 5th. They set a “peer perform” rating for the company. Raymond James Financial upgraded Oscar Health from a “market perform” rating to an “outperform” rating and set a $18.00 price objective for the company in a research note on Thursday, February 12th. UBS Group raised their price objective on Oscar Health from $15.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday, May 7th. Finally, Barclays raised their price objective on Oscar Health from $21.00 to $30.00 and gave the company an “equal weight” rating in a research note on Tuesday, May 26th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $20.22.

Key Headlines Impacting Oscar Health

Here are the key news stories impacting Oscar Health this week:

• Positive Sentiment: Wells Fargo upgraded Oscar Health from “strong sell” to “hold”, easing bearish sentiment even though its $20 target remains below the current share price. Zacks.com
• Positive Sentiment: Oscar Health’s recent earnings showed a major EPS beat, which supports the stock’s fundamental story despite revenue coming in below estimates.
• Neutral Sentiment: A company co-founder shifting into an advisory leadership role looks like an internal reorganization rather than a disruptive change. Oscar Health Co-Founder Shifts to Advisory Leadership Role
• Neutral Sentiment: Multiple insiders, including CFO Richard Scott Blackley and CAO Victoria Baltrus, sold shares under pre-planned 10b5-1 programs to cover tax obligations on vested equity awards, which is less concerning than discretionary selling.
• Negative Sentiment: Director Mario Schlosser sold 34,120 shares, the largest insider sale in the latest batch, which may pressure sentiment even though it was pre-arranged.

Institutional Investors Weigh In On Oscar Health

A number of institutional investors have recently modified their holdings of the stock. Bank of America Corp DE raised its stake in shares of Oscar Health by 205.1% in the 1st quarter. Bank of America Corp DE now owns 2,860,310 shares of the company’s stock valued at $32,808,000 after purchasing an additional 1,922,732 shares in the last quarter. Arkadios Wealth Advisors raised its stake in shares of Oscar Health by 9.4% in the 1st quarter. Arkadios Wealth Advisors now owns 14,275 shares of the company’s stock valued at $164,000 after purchasing an additional 1,228 shares in the last quarter. Amundi acquired a new stake in shares of Oscar Health in the 1st quarter valued at about $362,000. California State Teachers Retirement System raised its stake in shares of Oscar Health by 23.3% in the 1st quarter. California State Teachers Retirement System now owns 235,443 shares of the company’s stock valued at $2,701,000 after purchasing an additional 44,443 shares in the last quarter. Finally, Royal Bank of Canada raised its stake in shares of Oscar Health by 73.4% in the 1st quarter. Royal Bank of Canada now owns 282,904 shares of the company’s stock valued at $3,246,000 after purchasing an additional 119,714 shares in the last quarter. Institutional investors and hedge funds own 75.70% of the company’s stock.

About Oscar Health

Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.

The company’s primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.